-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

Benzinga·09/23/2026 12:11:02
Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.